ID: ALA2170750

Max Phase: Preclinical

Molecular Formula: C14H8FNO3S

Molecular Weight: 289.29

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(c1ccc(F)c(O)c1)c1nc2ccc(O)cc2s1

Standard InChI:  InChI=1S/C14H8FNO3S/c15-9-3-1-7(5-11(9)18)13(19)14-16-10-4-2-8(17)6-12(10)20-14/h1-6,17-18H

Standard InChI Key:  RIYCHKQKHFIRTQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 289.29

Molecular Weight (Monoisotopic): 289.0209

AlogP: 3.08

#Rotatable Bonds: 2

Polar Surface Area: 70.42

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.72

CX Basic pKa: 0.27

CX LogP: 3.49

CX LogD: 3.32

Aromatic Rings: 3

Heavy Atoms: 20

QED Weighted: 0.71

Np Likeness Score: -0.96

References

1. Spadaro A, Frotscher M, Hartmann RW..  (2012)  Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1.,  55  (5): [PMID:22277094] [10.1021/jm201711b]

2. Abdelsamie AS, Bey E, Gargano EM, van Koppen CJ, Empting M, Frotscher M..  (2015)  Towards the evaluation in an animal disease model: Fluorinated 17β-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme.,  103  [PMID:26322835] [10.1016/j.ejmech.2015.08.030]

Source

Source(1):

• Scientific Literature